You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Our Pipeline

A DIVERSE AND BALANCED PIPELINE APPROACH

We’re creating a diverse and balanced pipeline and platform to complement our poly (ADP-ribose) polymerase (PARP) inhibitor, niraparib, and our investigational PD-1 inhibitor, dostarlimab (TSR-042, anti-PD-1), across tumor types and targets. These combinations were carefully selected to inform individual tumor strategies in areas of unmet need, involving novel combinations with different mechanisms of action. Our pipeline approach is guided by applying science for patients first, all with the goal of bringing potentially transformative therapies to people living with cancer.

Discovery Pre-clinical Phase 1 Phase 2 Phase 3
TESARO Compound Trial Name & Indication
TESARO Compound:
Nirapariba

Trial Name & Cancer Type:
PRIMA: Ovarian Cancer Maintenance (First Line)

NCT02655016

TESARO Compound:
Niraparib
Dostarlimabb

Trial Name & Cancer Type:
FIRST: Ovarian Cancer Treatment and Maintenance (First Line) Chemotherapy Alone and in Combination With Dostarlimab Followed by Maintenance Niraparib Alone and in Combination With Dostarlimab*

NCT03602859

TESARO Compound:
Niraparib

Trial Name & Cancer Type:
QUADRA: Recurrent Ovarian Cancer Treatment (Fourth Line or Later)

NCT02354586

TESARO Compound:
Niraparib

Trial Name & Cancer Type:
OVARIO: Ovarian Cancer Maintenance (First Line) in Combination With Bevacizumab

NCT03326193

TESARO Compound:
Niraparib
Dostarlimab

Trial Name & Cancer Type:
JASPER: Advanced Non-Small Cell Lung Cancer (NSCLC) in Combination With Dostarlimab

NCT03308942

TESARO Compound:
Niraparib
Dostarlimab

Trial Name & Cancer Type:
MOONSTONE: Platinum-Resistant Ovarian Cancer

NCT03955471

TESARO Compound:
Niraparib
Dostarlimab

Trial Name & Cancer Type:
OPAL: Platinum-Resistant Ovarian Cancer (Second or Third Line) in Combination With Dostarlimab and Bevacizumab

NCT03574779

TESARO Compound:
Dostarlimab

Trial Name & Cancer Type:
GARNET: Microsatellite Instability High (MSI-H) Tumors (Including Metastatic Endometrial Cancer), Microsatellite Stable (MSS) Endometrial Cancer, and NSCLC

NCT02715284

TESARO Compound:
TSR-022c
Dostarlimab

Trial Name & Cancer Type:
AMBER: Melanoma, NSCLC, and Colorectal Cancer Alone and in Combination With Dostarlimab

NCT02817633

TESARO Compound:
TSR-033d
Dostarlimab

Trial Name & Cancer Type:
CITRINO: Various Tumor Types Alone and in Combination With Dostarlimab

NCT03250832

TESARO Compound:
Niraparib

Trial Name & Cancer Type:
Neoadjuvant Treatment in HER2- and BRCAMut Breast Cancer

NCT03329937

a: PARP Inhibitor
b: anti-PD-1 mAb
c: anti-TIM-3 mAb
d: anti-LAG-3 mAb

*In collaboration with the European Network for Gynaecological Oncological Trial groups (ENGOT). Bevacizumab may be included as part of the chemotherapy and maintenance regimen per local standard of care.

BRCA, breast cancer susceptibility gene; HER, human epidermal growth factor receptor; mAb, monoclonal antibody; PARP, poly ADP ribose polymerase.